Home > Insider Trading > Filing (0001104659-24-006678)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
727207	Accelerate Diagnostics Inc	AXDX	Laboratory Analytical Instruments (3826)	841072256

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1377832	Matthew Strobeck	C/O Accelerate Diagnostics, Inc. 3950 S. Country Club Road, Suite 470 Tucson AZ 85714		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-01-23	100,000	$0.00	120,682	No	4	P	Indirect	By Birchview Fund, LLC

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Birchview Fund, LLC

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Common Stock Warrants (right to buy)	Acquisiton	2024-01-23	100,000	$0.00	100,000	$1.65

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
100,000	2024-01-23	2029-01-23	No	4	P	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	202,556	Direct
Common Stock	2,000	Indirect	As UGMA Custodian for minor children

Footnotes

The reported securities are included within 100,000 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit in an underwritten public offering. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock.
The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.